Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities

Research in Developmental Disabilities

Volumn 30, Issue 4, 2009, Pages 613-669

  de Leon, Jose ^a,b   Greenlee, Brian ^c   Barber, Jack ^d,e   Sabaawi, Mohamed ^f   Singh, Nirbhay N ^g  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c Bluegrass Communities at Oakwood   (United States)

^d Western State Hospital Staunton   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g ONE RESEARCH INSTITUTE   (United States)

Author keywords

Antipsychotic medication; Aripiprazole; Individuals with intellectual disabilities; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLARITHROMYCIN; CLOZAPINE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; RIFAMPICIN; RISPERIDONE; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DISORDER; BIPOLAR MANIA; COMORBIDITY; CONSTIPATION; COST BENEFIT ANALYSIS; DEMENTIA; DEPRESSION; DIABETIC COMA; DOSE RESPONSE; DRUG ABUSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EXTRAPYRAMIDAL SYNDROME; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; INTELLECTUAL IMPAIRMENT; LIPID BLOOD LEVEL; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MORNING DOSAGE; MORTALITY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIAPISM; PROLACTIN BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; STROKE; TORSADE DES POINTES; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG EVALUATION; EVIDENCE-BASED MEDICINE; HUMANS; MENTAL RETARDATION; MENTALLY DISABLED PERSONS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS;

EID: 60849099314     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2008.10.010     Document Type: Review

References (189)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., and Infante M.C. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
2. Alper K., Schwartz K.A., Kolts R.L., and Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biological Psychiatry 62 (2007) 345-354
3. Aman M.G., and Madrid A. Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 5 (1999) 253-263
4. Aman M.G., Gharabawi G.M., and Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients with Mental Retardation and Developmental Disabilities. Treatment of behavior disorders in mental retardation: Report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Journal of Clinical Psychiatry 65 (2004) 1197-1210
5. American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), American Psychiatric Association (APA), and North American Association for the Study of Obesity (NAASO). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
6. Ananth J., Parameswaran S., Gunatilake S., Burgoune K., and Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65 (2004) 464-470
7. Anderson, C. B., True, J. E., Ereshefsky, L., Miller, A. L., Peters, B. L., & Velligan, D. I. (1993, May). Risperidone dose, plasma levels and response (NR 217, p. 113). San Francisco, CA: 1993 New Research Program and Abstracts, American Psychiatric Association Annual Meeting.
8. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clinical Pharmacokinetics 44 (2005) 989-1008
9. Armstrong S.C., Cozza K.L., and Sandson N.B. Six patterns of drug-drug interactions. Psychosomatics 44 (2003) 255-258
10. Arranz M.J., and de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Molecular Psychiatry 12 (2007) 707-747
11. Astra Zeneca. Seroquel (quetiapine fumarate tablets) package insert (2007), Astra Zeneca, Wilmington, DE
12. Astra Zeneca. Seroquel XR (quetiapine fumarate extended release tablets) package insert (2007), Astra Zeneca, Wilmington, DE
13. Auquier P., Lançon C., Rouillon F., and Lader M. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety 16 (2007) 1308-1312
14. Barbui C., Lintas C., and Percudan M. Head-to-head comparison of the costs of atypical antipsychotics: A systematic review. CNS Drugs 19 (2005) 935-950
15. Barnard L., Young A.H., Pearson J., Geddes J., and O'Brien G. A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology 16 (2002) 93-101
16. Basil B., Mathews M., Adetunji B., and Budur K. The CATIE study [Letter]. American Journal of Psychiatry 163 (2006) 555
17. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
18. Bialer M., Doose D.R., Murthy B., Curtin C., Wang S.S., and Schwabe S. Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics 43 (2004) 763-780
19. Bobes J., Garcia-Portilla M.P., Saiz P.A., Bascaran M.T., Bousoño M., and Arango C. High degree of tolerability for monotherapy with high doses of quetiapine: A case report. Journal of Clinical Psychiatry 63 (2002) 1048-1049
20. Bodfish J.W., Newell K.M., Sprague R.L., Harper V.N., and Lewis M.H. Dyskinetic movement disorder among adults with mental retardation: Phenomenology and co-occurrence with stereotypy. American Journal on Mental Retardation 101 (1996) 118-129
21. Botts S., Diaz F.J., Santoro V., Spina E., Muscatello M.R., Cogollo M., Castro F.E., and de Leon J. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32 (2008) 1453-1458
22. Burns M.J. The pharmacology and toxicology of atypical antipsychotic agents. Journal of Toxicology. Clinical Toxicology 39 (2001) 1-14
23. Capel M.M., Colbridge M.G., and Henry J.A. Overdose profiles of new antipsychotic agents. International Journal of Neuropsychopharmacology 3 (2000) 1-54
24. Cheng-Shannon J., McGough J.J., Pataki C., and McCracken J.T. Second-generation antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 14 (2004) 372-394
25. Chew M.L., Mulsant B.H., Pollock B.G., Pollock B.G., Lehman M.E., Greenspan A., et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research 88 (2006) 63-72
26. Citrome L., Jaffe A., Levine J., and Lindenmayer J.P. Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. Journal of Clinical Psychiatry 66 (2005) 1512-1516
27. Clevenger C.V., Furth P.A., Hankinson S.E., and Schuler L.A. The role of prolactin in mammary carcinoma. Endocrine Reviews 24 (2003) 1-27
28. Cohen L.S. Treatment of bipolar disorder during pregnancy. Journal of Clinical Psychiatry 68 Suppl. 9 (2007) 4-9
29. Cohen S., Fitzgerald B., Okos A., Khan S., and Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry 64 (2003) 60-62
30. Cohn T.A., and Sernyak M.J. Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry 51 (2006) 492-501
31. Correll C.U., and Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review. Journal of Child and Adolescent Psychopharmacology 17 (2007) 647-656
32. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 161 (2004) 414-425
33. Cutler A.J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28 (2003) 69-82
34. D'Arrigo C., Migliardi G., Santoro V., and Spina E. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Therapeutic Drug Monitoring 28 (2006) 388-393
35. de Leon J. Psychopharmacology: Atypical antipsychotic dosing: The effect of smoking and caffeine. Psychiatric Service 55 (2004) 491-493
36. de Leon J. Psychopharmacology: Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants. Psychiatric Services 55 (2004) 125-128
37. de Leon J. The AmpliChip CYP450 Test: Personalized medicine has arrived in psychiatry. Expert Review of Molecular Diagnostics 6 (2006) 277-286
38. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: A naturalistic study. European Archives of Psychiatry and Clinical Neurosciences 257 (2007) 169-172
39. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial). Journal of Clinical Psychopharmacology 28 (2008) 125-131
40. de Leon J., Armstrong S.C., and Cozza K.L. The dosing of atypical antipsychotics. Psychosomatics 46 (2005) 262-273
41. de Leon J., and Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: The clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophrenia Research 96 (2007) 185-197
42. de Leon J., Sandson N.B., and Cozza K.L. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part II. Psychosomatics 49 (2008) 347-361
43. de Leon J., Stanilla J.K., White A.O., and Simpson G.M. Anticholinergics to treat clozapine withdrawal [Letter]. Journal of Clinical Psychiatry 55 (1994) 119-120
44. de Leon J., Susce M.T., and Murray-Carmichael E. The AmpliChip CYP450 Genotyping Test: Integrating a new clinical tool. Molecular Diagnosis and Therapy 10 (2006) 135-151
45. de Leon J., Susce M.T., Pan R.M., Fairchild M., Koch W., and Wedlund P.J. CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Journal of Clinical Psychiatry 66 (2005) 15-27
46. de Leon J., Susce M.T., Pan R.M., Wedlund P.J., Orrego M.L., and Diaz F.J. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40 (2007) 93-102
47. Delassus-Guenault N., Jegouzo A., Odou P., Seguret T., Zangerlin H., Vignole E., et al. Clozapine-olanzapine: A potentially dangerous switch. A report of two cases. Journal of Clinical Pharmacy and Therapeutics 24 (1999) 191-195
48. Dobbs R.L., Brahm N.C., Fast G., and Brown R.C. Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent. Annals of Pharmacotherapy 38 (2004) 1541-1542
49. Dolder C.R., and Jeste D.V. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biological Psychiatry 53 (2003) 1142-1145
50. Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: Does newer necessarily mean safer?. Current Opinion in Pediatrics 17 (2005) 227-233
51. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 24 (2005) 1-31
52. Editor. Generic Zyprexa in Canada attracting US sz consumers. Schizophrenia Digest (2008, Winter) 14-15
53. R Intramuscular olanzapine for injection (2007), Eli Lilly and Company, Indianapolis, IN
54. Faulkner G., and Cohn T.A. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Canadian Journal of Psychiatry 51 (2006) 502-511
55. Fava M. Weight gain and antidepressants. Journal of Clinical Psychiatry 61 Suppl. 11 (2000) 37-41
56. Feinstein A.R. Twentieth century paradigms that threaten both scientific and humane medicine in the twenty-first century. Journal of Clinical Epidemiology 49 (1996) 615-617
57. Feinstein A.R., and Horwitz R.I. Problems in the "Evidence" of "Evidence-based medicine". American Journal of Medicine 103 (1997) 529-535
58. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Treatment of psychosis in Parkinson's disease: Safety considerations. Drug Safety 26 (2003) 643-659
59. Fitzgerald B., and Okos A. Elevation of carbamazepine-10,11-epoxide by quetiapine. Pharmacotherapy 22 (2002) 1500-1503
60. Fraunfelder F.W. Twice-yearly exams unnecessary for patients taking quetiapine. American Journal of Ophthalmology 138 (2004) 870-871
61. Freedman R., Carpenter Jr. W.T., Davis J.M., Goldman H.H., Tamminga C.A., and Thomas M. The costs of drugs for schizophrenia. American Journal of Psychiatry 163 (2006) 2029-2031
62. Friedlander R., Lazar S., and Klancnik J. Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry 46 (2001) 741-745
63. Fulda T.R., Lyles A., Pugh M.C., and Christensen D.B. Current status of prospective drug utilization review. Journal of Managed Care Pharmacy 10 (2004) 433-441
64. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Therapeutic Drug Monitoring 25 (2003) 46-53
65. Gold L.H. Use of psychotropic medication during pregnancy: Risk management guidelines. Psychiatric Annals 30 (2000) 421-432
66. Gómez-Criado M.S., Bernardo M., Florez T., Gutiérrez J.R., Gandía R., and Ayani I. Ziprasidone overdose: Cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy 25 (2005) 1660-1665
67. Gunasekara N.S., and Spencer C.M. Quetiapine: A review of its use in schizophrenia. CNS Drugs 9 (1998) 325-340
68. Gunasekara N.S., Spencer C.M., and Keating G.M. Ziprasidone: A review of its use in schizophrenia and schizoaffective disorders. Drugs 62 (2002) 1217-1251
69. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
70. Haro J.M., and Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: Implications for the treatment of schizophrenia. CNS Drugs 20 (2006) 293-301
71. Harrigan E.P., Miceli J.J., Anziano R., Watsky E., Reeves K.R., Neal R.C., et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 24 (2004) 62-69
72. Harrison M.O., and Krishnan K.R. Antipsychotic medications and sudden cardiac death. Psychopharmacology Bulletin 36 (2002) 91-99
73. Harrison T.S., and Perry C.P. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorders. Drugs 64 (2004) 1715-1736
74. Hellings J.A., Zarcone J.R., Reese R.M., Valdovinos M.G., Marquis J.G., Fleming K.K., et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. Journal of Autism and Developmental Disorders 36 (2006) 401-411
75. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence?. CNS Drugs 16 (2002) 77-89
76. Hendset M., Haslemo T., Rudberg I., Refsum H., and Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 39 (2006) 121-127
77. Herrmann N., and Lanctôt K.L. Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned?. Drug Safety 29 (2006) 833-843
78. Hiemke C., Dragicevic A., Gründer G., Hätter S., Sachse J., Vernaleken I., et al. Therapeutic monitoring of new antipsychotic drugs. Therapeutic Drug Monitoring 26 (2004) 156-160
79. Hodge L.S., and Tracy T.S. Alterations in drug disposition during pregnancy: Implications for drug therapy. Expert Opinion on Drug Metabolism & Toxicology 3 (2007) 557-571
80. Hollander E., Phillips A.T., and Yeh C.C. Targeted treatments for symptom domains in child and adolescent autism. Lancet 362 (2003) 732-734
81. Hope T. Evidence based medicine and ethics. Journal of Medical Ethics 21 (1995) 259-260
82. Hussain M.Z., Waheed W., and Hussain S. Intravenous quetiapine abuse. American Journal of Psychiatry 162 (2005) 1755-1756
83. Iqbal N., Lambert T., and Masand P. Akathisia: Problem of history or concern of today. CNS Spectrums 12 9 Suppl. 14 (2007) 1-13
84. Janowsky D.S., Barnhill L.J., and Davis J.M. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: A retrospective, open-label, naturalistic trial. Journal of Clinical Psychiatry 64 (2003) 1258-1265
85. Janowsky D.S., Barnhill L.J., Khalid A.S., and Davis J.M. Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. Journal of Clinical Psychiatry 67 (2006) 1272-1277
86. Janowsky D.S., Barnhill L.J., Shetty M., and Davis J.M. Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. Journal of Clinical Psychopharmacology 25 (2005) 19-25
87. Janssen. Invega™ Extended-release tablets package insert (2007), Janssen, Titusville, NJ
88. R (risperidone) orally disintegrating tablets (2007), Janssen, Titusville, NJ
89. R (risperidone) long-acting injection (2007), Janssen, Titusville, NJ
90. Jenicek M., and Hitchcock D. Evidence-based practice: Logic and critical thinking in medicine (2005), American Medical Association Press, Chicago
91. Kales H.C., Valenstein M., Kim H.M., McCarthy J.F., Ganoczy D., Cunningham F., et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry 164 (2007) 1568-1576
92. Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research 90 (2007) 147-161
93. Kane J.M. Tardive dyskinesia circa 2006. American Journal of Psychiatry 163 (2006) 1316-1318
94. Katz I.R. Optimizing atypical antipsychotic treatment strategies in the elderly. Journal of American Geriatrics Society 52 12 Suppl. (2004) S272-S277
95. Kim D.R., and Staab J.P. Quetiapine discontinuation syndrome [Letter]. American Journal of Psychiatry 162 (2005) 1020
96. Kim E., Levy R., and Pikalov A. Personalized treatment with atypical antipsychotics. Advances in Therapy 24 (2007) 721-740
97. Kinon B.J., Basson B.R., Gilmore J.A., and Tollefson G.D. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry 62 (2001) 92-100
98. Knotterus A., and Dinant G.J. Medicine based evidence: A prerequisite for evidence based medicine. British Medical Journal 315 (1997) 1109-1110
99. Koller E.A., Cross J.T., Doraiswamy M., and Schneider B.S. Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy 23 (2003) 735-744
100. Koller E.A., Cross J.T., Doraiswamy M., and Malozowski S.N. Pancreatitis associated with antipsychotics: From the Food and Drug Administration's MedWatch Surveillance system and published reports. Pharmacotherapy 23 (2003) 1123-1130
101. Koller E.A., Weber J., Doraiswamy P.M., and Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Journal of Clinical Psychiatry 65 (2004) 857-863
102. Kwok K., and Cheung P.W.H. Co-morbidity of psychiatric disorder and medical illness in people with intellectual disabilities. Current Opinion in Psychiatry 20 (2007) 443-449
103. Laimer M., Kramer-Reinstadler K., Rauchenzauner M., Lechner-Schoner T., Strauss R., Engl J., et al. Effect of mirtazapine treatment on body composition and metabolism. Journal of Clinical Psychiatry 67 (2006) 421-424
104. Lambert T.J. Switching antipsychotic therapy: What to expect and clinical strategies for improving therapeutic outcomes. Journal of Clinical Psychiatry 68 Suppl. 6 (2007) 10-13
105. Lee P.E., Sykora K., Gill S., Mandamni M., Marras C., Anderson G.M., et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: A population-based cohort study in older adults. Journal of the American Geriatrics Society 53 (2005) 1374-1379
106. Lemmens P., Brecher M., and Van Baelen B. A combined analysis of double-blind studies of risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms. Acta Psychiatrica Scandinavica 99 (1999) 160-170
107. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of new antipsychotics olanzapine, quetiapine, risperidone, and sertrindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophrenia Research 35 (1999) 51-68
108. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
109. Liperoti R., Pedone C., Lapane K.L., Mor V., Bernabei R., and Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine 165 (2005) 2677-2682
110. Lowey E.H. Ethics and evidence-based medicine: Is there a conflict?. Medscape General Medicine 9 (2007) 30. http://www.medscape.com/viewarticle/559977 Available at: www.medscape.com/viewarticle/559977.
111. Mago R., Anolik R., Johnson R.A., and Kunkel E.J.S. Recurrent priapism associated with use of aripiprazole. Journal of Clinical Psychiatry 67 (2006) 1471-1472
112. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161 (2004) 1334-1349
113. Markham-Abedi C., McNeely C., and de Leon J. Ziprasidone-induced catatonia symptoms [Letter]. Journal of Neuropsychiatry and Clinical Neurosciences 19 (2007) 476-477
114. Masi G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs 18 (2004) 1031-1052
115. Matson J.L., and Wilkins J. Antipsychotic drugs for aggression in intellectual disability. Lancet 371 (2008) 9-10
116. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics. Clinical Pharmacokinetics 46 (2007) 359-388
117. May P., London E.B., Zimmerman T., Thompson R., Mento T., and Spreat S. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Annals of Clinical Psychiatry 7 (1995) 155-160
118. McCracken J.T., McGough J., and Shah B. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 347 (2002) 314-321
119. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry 162 (2005) 1142-1148
120. McGavin J.K., and Goa K.L. Aripiprazole. CNS Drugs 16 (2002) 779-786
121. McKenna K., Koren G., Tetelbaum M., Wilton L., Shakir S., Diav-Citrin O., et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. Journal of Clinical Psychiatry 66 (2005) 444-449
122. Melkersson K.I., Dahl M.L., and Hulting A.L. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 175 (2004) 1-6
123. Melkersson K., and Hulting A.L. Prolactin-secreting pituitary adenoma in neuroleptic-treated patients with psychotic disorder. European Archives of Psychiatry and Clinical Neurosciences 250 (2000) 6-10
124. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Research 70 (2004) 1-17
125. Michaelides C., Thakore-James M., and Durso R. Reversible withdrawal dyskinesia associated with quetiapine. Movement Disorders 20 (2005) 769-770
126. Miller K.K. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectrums 9 8 Suppl. 7 (2004) 28-32
127. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia. American Journal of Psychiatry 164 (2007) 630-637
128. Moore T.J., Cohen M.R., and Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2003. Archives of Internal Medicine 167 (2007) 1752-1759
129. Nasrallah H.A. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry 18 (2006) 57-62
130. Nasrallah H.A., and Tandon R. Efficacy, safety and tolerability of quetiapine in patients with schizophrenia. Journal of Clinical Psychiatry 63 Suppl. 13 (2002) 12-20
131. Nayudu S.K., and Scheftner W.A. Case report of withdrawal syndrome after olanzapine discontinuation. Journal of Clinical Psychopharmacology 20 (2000) 489-490
132. Newcomer J.W. Metabolic consideration in the use of antipsychotic medications: A review of recent use. Journal of Clinical Psychiatry 68 Suppl. 1 (2007) 20-27
133. Newcomer J.W., and Haupt D.W. The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51 (2006) 480-491
134. Newport D.J., Calamaras M.R., DeVane C.L., Donovan J., Beach A.J., Winn S., et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. American Journal of Psychiatry 164 (2007) 1214-1220
135. Olesen O.V., and Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication. Therapeutic Drug Monitoring 21 (1999) 87-90
136. Otsuka Pharmaceutical Company. Abilify (2007), Otsuka, Tokyo, Japan
137. Palermo M.T., and Curatolo P. Pharmacologic treatment of autism. Journal of Child Neurology 19 (2004) 155-164
138. Peng C.C., Glassman P.A., Marks I.R., Fowler C., Castiglione B., and Good C.B. Retrospective drug utilization review: Incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. Journal of Managed Care Pharmacy 9 (2003) 513-522
139. R (ziprasidone mesylate) for injection for IM use only (2007), Pfizer, New York, NY
140. Pierre J.M., Shnayder I., Wirshing D.A., and Wirshing W.C. Intranasal quetiapine abuse [Letter]. American Journal of Psychiatry 161 (2004) 1718
141. Pinta E.R., and Taylor R.E. Quetiapine addiction? [Letter]. American Journal of Psychiatry 164 (2007) 174-175
142. Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Safety 19 (1998) 57-72
143. Raja M., and Azzoni A. Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology 4 (2001) 393-397
144. Reeves R.R., and Brister J.C. Additional evidence of the abuse potential of quetiapine. Southern Medical Journal 100 (2007) 834-836
145. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry 162 (2005) 1361-1369
146. Rochon P.A., Stukel T.A., Sykora K., Gill S., Garfinkel S., Anderson G.M., et al. Atypical antipsychotics and parkinsonism. Archives of Internal Medicine 165 (2005) 1882-1888
147. Rogers T., de Leon J., and Atcher D. Possible interaction between warfarin and quetiapine. Journal of Clinical Psychopharmacology 19 (1999) 382-383
148. Rosenbaum J.F., Arana G.W., Hyman S.E., Labbate L.A., and Fava M. Handbook of psychiatric drug therapy. 5th ed. (2005), Lippincott, Williams & Wilkins, Philadelphia, PA
149. Rosenheck R.A., Leslie D.L., Sindelar J., Miller E.A., Lin H., Stroup T.S., et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163 (2006) 2080-2089
150. Rosenstock J., Hollander P., Gadde K.M., Sun X., Strauss R., Leung A., et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30 (2007) 1480-1486
151. Sabaawi M., Singh N.N., and de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Research in Developmental Disabilities 27 (2006) 309-336
152. Sachdev P. Drug-induced movement disorders in institutionalized adults with mental retardation: Clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry 26 (1992) 242-248
153. Sachdev P.S. The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry 34 (2000) 355-369
154. Saha S., Chant D., and McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?. Archives of General Psychiatry 64 (2007) 1123-1131
155. Sandson N.B., Armstrong S.C., and Cozza K.L. An overview of psychotropic drug-drug interactions. Psychosomatics 46 (2005) 464-494
156. Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007). Comparative safety of conventional and atypical antipsychotic medications: Risk of death in British Columbia seniors (Effective Health Care Research Report No. 2). Rockville, MD: Agency for Healthcare Research and Quality. Available at www.effectivehealthcare.ahrq.gov/reports/final.cfm.
157. Shastri M., Alla L., and Sabaratnam M. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: A case series. Journal of Psychopharmacology 20 (2006) 863-867
158. Shekelle, P., Maglione, M., Bagley, S., Suttorp, M., Mojica, W. A., Carter, J., et al. (2007). Comparative effectiveness of off-label use of atypical antipsychotics (Comparative Effectiveness Review No. 6). Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
159. Simpson B.R., and Albanese Jr. R.P. Ziprasidone and hypokalemia: A case of 2 predisposing factors for QTc prolongation without development of torsades de pointes. Primary Care Companion to the Journal of Clinical Psychiatry 7 (2005) 134-136
160. Simpson G.M., Amin M., and Kunz E. Withdrawal effects of phenothiazines. Comprehensive Psychiatry 6 (1994) 347-351
161. Singh A.N., Matson J.L., Cooper C.L., Dixon D., and Sturmey P. The use of risperidone among individuals with mental retardation: Clinically supported or not?. Research in Developmental Disabilities 26 (2005) 203-218
162. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. Journal of the American Medical Association 293 (2005) 596-608
163. Sovner R. Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: Two case reports. Mental Retardation 33 (1995) 221-225
164. Spina E., and de Leon J. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic & Clinical Pharmacology & Toxicology 100 (2007) 4-22
165. Sprague R.L., Kalachnik J.E., Breuning S.E., Davis V.J., Ullman R.K., Callari S., et al. The Dyskinesia Identification System-Coldwater (DIS-Co): A tardive dyskinesia rating scale for the developmentally disabled. Psychopharmacology Bulletin 20 (1984) 328-338
166. Stanilla J.K., de Leon J., and Simpson G.M. Clozapine withdrawal resulting in delirium with psychosis: A report of three cases. Journal of Clinical Psychiatry 58 (1997) 252-255
167. Sullivan G., Bienroth M., Jones M., Millar H., Ratna L., and Taylor D. Practical prescribing with aripiprazole in schizophrenia: Consensus recommendations of a UK multidisciplinary panel. Current Medical Research and Opinion 7 (2007) 1733-1734
168. Tandon R., Targum S.D., Nasrallah H.A., Ross R., and Treatment Effectiveness in Schizophrenia Consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Journal of Psychiatric Practice 12 (2006) 348-363
169. Tarasoff G., and Osti K. Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada [Letter]. American Journal of Psychiatry 164 (2007) 350
170. The U.S. Pharmacopeia Drug Utilization Review Advisory Panel. Drug utilization review: Mechanisms to improve its effectiveness and broaden its scope. Journal of the American Pharmaceutical Association 40 (2000) 538-545
171. Thurstone C.C., and Alahi P.J. A possible case of quetiapine withdrawal syndrome. Journal of Clinical Psychiatry 61 (2000) 602-603
172. Titier K., Girodet P.O., Verdoux H., Molimard M., Bégaud B., Haverkamp W., et al. Atypical antipsychotics: From potassium channels to torsade de pointes and sudden death. Drug Safety 28 (2005) 35-51
173. Travis M.J., Burns T., Fahy T., Frangiu S., Gray R., Haddad P.M., et al. Aripiprazole in schizophrenia: Consensus guidelines. International Journal of Clinical Practice 59 (2005) 485-495
174. Trenton A., Currier G., and Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 17 (2003) 307-324
175. Tuncer C., Cokkeser Y., Komsuoglu B., Ozdemir R., Güven A., Pekdemir H., et al. Assessment of ventricular repolarization in deaf-mute children. Pediatric Cardiology 21 (2000) 135-140
176. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. Lancet 371 (2008) 57-63
177. Van Putten T., and Marder S.R. Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry 68 (1987) l3-l9
178. Verhelst J., and Abs R. Hyperprolactinemia: Pathophysiology and management. Treatments in Endocrinology 2 (2003) 23-32
179. 14C-paliperidone 1 mg in healthy subjects. European Neuropsychopharmacology 15 Suppl. 3 (2005) S648-S649
180. Waters B.M., and Joshi K.G. Intravenous quetiapine-cocaine use ("Q-ball"). American Journal of Psychiatry 164 (2007) 173-174
181. Weiden P.J., Preskorn S.H., Fahnestock P.A., Carpenter D., Ross R., and Docherty J.P. Roadmap Survey. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: A roadmap. Journal of Clinical Psychiatry 68 Suppl. 7 (2007) 1-48
182. Weigmann H., Gerek S., Zeisig A., Müller M., Härtter S., and Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring 23 (2001) 410-413
183. West L., and Waldrop J. Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatric Nursing 32 (2006) 545-549
184. Wilkinson J.E., Culpepper L., and Cerreto M. Screening tests for adults with intellectual disabilities. Journal of the American Board of Family Medicine 20 (2007) 399-407
185. Williams R. Optimal dosing with risperidone: Updated recommendations. Journal of Clinical Psychiatry 62 (2001) 282-289
186. Wszola B.A., Newell K.M., and Sprague R.L. Risk factors for tardive dyskinesia in a large population of youths and adults. Experimental and Clinical Psychopharmacology 9 (2001) 285-296
187. Yaeger D., Smith H.G., and Altshuler L.L. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. American Journal of Psychiatry 163 (2006) 2064-2070
188. Yoon G., Quitania L., Kramer J.H., Fu Y.H., Miller B.L., and Ptácek L.J. Andersen-Tawil syndrome: Definition of a neurocognitive phenotype. Neurology 66 (2006) 1703-1710
189. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. Journal of Psychiatric Research 37 (2003) 193-220